Why the study?
Does sacubitril/valsartan improve diastolic function in mice with obesity-related metabolic heart disease?
Does sacubitril/valsartan improve diastolic function in mice with obesity-related metabolic heart disease?
Neprilysin inhibition with sacubitril/valsartan exerts favorable effects on diastolic function and interstitial fibrosis beyond ARB therapy alone in a mouse model of obesity-related metabolic heart disease.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice in metabolic heart disease; hypothesis-generating for neprilysin inhibition in diastolic dysfunction.
Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or an equivalent dose of VAL for 4 months. There were striking differences between SAC/VAL and VAL with regard to: 1) diastolic dysfunction; 2) interstitial fibrosis; and to a lesser degree; 3) oxidative stress—all of which were more favorably affected by SAC/VAL. SAC/VAL and VAL similarly attenuated myocardial hypertrophy and improved myocardial energetics. In mice with obesity-related MHD, neprilysin inhibition exerts favorable effects on diastolic function.
No takes yet. Share an insight, caveat, or question.
Croteau et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: